E. Dow

发表

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

D. Esseltine, K. Anderson, P. Sonneveld, 2017, British journal of haematology.

Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.

P. Kouides, F. Peyvandi, E. Berntorp, 2019, Blood reviews.

Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.

J. Lokich, M. Bern, E. Dow, 1998, European journal of cancer.

The multifractionated, twice‐weekly dose schedule for a three‐drug chemotherapy regimen

J. Lokich, M. Bern, E. Dow, 1999, Cancer.

Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas

J. Lokich, M. Bern, E. Dow, 1999, Cancer.

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

S. McCachren, G. Otterson, M. Villalona-Calero, 2004, Clinical Cancer Research.

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

S. McCachren, G. Otterson, M. Villalona-Calero, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

M. Dimopoulos, A. Palumbo, P. Richardson, 2015, American journal of hematology.

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

A Phase I / II Study of LY 900003 , an Antisense Inhibitor of Protein Kinase C-, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non – Small Cell Lung Cancer

S. McCachren, G. Otterson, M. Villalona-Calero, 2004 .

Multi-day fractionated administration schedule for paclitaxel.

J. Lokich, M. Bern, C. Moore, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer.

C. Drescher, H. Youssoufian, O. Shebanova, 2018, Annals of Oncology.

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.

H. Youssoufian, O. Shebanova, Joyce F. Liu, 2018 .

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer.

C. Drescher, H. Youssoufian, O. Shebanova, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.